This core will support pharmacokinetic (PK) studies for laboratory and animal nanoART investigations. In project 2, H. Gendelman mice will receive a single oral dose of individual nanoART drugs to characterize reference PK parameters. A starting single dose in mice will be scaled from the dose recommended in humans based on body-surface area (shape factor) normalization. PK, tissue distribution, blood brain barrier (BBB) penetration, and toxicity will be compared between the nanoART and free drug. Next, both nanoART and free ART will be administered to two models of infected mice as a part of a dose efficacy study. Plasma and target tissue concentrations will be determined. In project 3, multiple dose PK studies similar to that in mice will be performed in uninfected monkeys. A starting single dose in monkeys will be scaled from the dose recommended in humans based on body-surface area (shape factor) normalizations. PK parameters and linearities will be assessed by comparing PK results across dosing ranges. PK, tissue distribution, BBB penetration, and toxicity will be compared between the nanoART and free ART. Next, multiple dose efficacy studies will be performed in rhesus monkeys. The multiple dosing efficacy study will aim to achieve and maintain systemic exposure levels similar to that recommended in humans without exceeding the peak exposure levels reported in humans. The multiple dosing regimen will be designed from the single dose PK parameters. Hematology and chemistry panels will be monitored, and plasma drug concentrations measured for up to 14 weeks following multiple drug administration. Monkeys will be closely monitored for adverse events including blood pressure, pulse and cardiac rhythm, liver enzymes and renal function, and potential infusion reactions. In addition to close monitoring of safety parameters and PK analyses, the animals will undergo cerebrospinal fluid evaluations of HIV viral load and neuroinflammatory biomarkers at baseline and eight weeks on study (H. Fox, project 3). The long-term goal is to develop injectable nanoART for human use. If successful the work could lead to novel formulations that improve medication adherence, and thereby therapeutic outcomes, and novel treatment applications to include enhanced penetration into viral sanctuaries as the central nervous system. This core is already operative and has generated the preliminary data shown in project 2 (H. Gendelman) supporting the abilities to integrate each of the projects into one program.

Public Health Relevance

;The goal of attaining long acting antiretroviral therapies for HIV/AIDS would have dramatic positive consequence for the course and access of HIV/AIDS and particularly pertinent for substance abusers and in resource limited settings.

National Institute of Health (NIH)
National Institute on Drug Abuse (NIDA)
Research Program Projects (P01)
Project #
Application #
Study Section
Special Emphasis Panel (ZRG1-AARR-D)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of Nebraska Medical Center
United States
Zip Code
Olson, Katherine E; Gendelman, Howard E (2016) Immunomodulation as a neuroprotective and therapeutic strategy for Parkinson's disease. Curr Opin Pharmacol 26:87-95
Olson, Katherine E; Bade, Aditya N; Schutt, Charles R et al. (2016) Manganese-Enhanced Magnetic Resonance Imaging for Detection of Vasoactive Intestinal Peptide Receptor 2 Agonist Therapy in a Model of Parkinson's Disease. Neurotherapeutics 13:635-46
Ivanisevic, Julijana; Stauch, Kelly L; Petrascheck, Michael et al. (2016) Metabolic drift in the aging brain. Aging (Albany NY) 8:1000-20
Li, Weizhe; Tong, Hsin-I; Gorantla, Santhi et al. (2016) Neuropharmacologic Approaches to Restore the Brain's Microenvironment. J Neuroimmune Pharmacol 11:484-94
Singh, Dhirender; McMillan, JoEllyn; Hilaire, James et al. (2016) Development and characterization of a long-acting nanoformulated abacavir prodrug. Nanomedicine (Lond) 11:1913-27
Sajja, Balasrinivasa R; Bade, Aditya N; Zhou, Biyun et al. (2016) Generation and Disease Model Relevance of a Manganese Enhanced Magnetic Resonance Imaging-Based NOD/scid-IL-2Rγc(null) Mouse Brain Atlas. J Neuroimmune Pharmacol 11:133-41
Bade, Aditya N; Gorantla, Santhi; Dash, Prasanta K et al. (2016) Manganese-Enhanced Magnetic Resonance Imaging Reflects Brain Pathology During Progressive HIV-1 Infection of Humanized Mice. Mol Neurobiol 53:3286-97
Zhang, Gang; Guo, Dongwei; Dash, Prasanta K et al. (2016) The mixed lineage kinase-3 inhibitor URMC-099 improves therapeutic outcomes for long-acting antiretroviral therapy. Nanomedicine 12:109-22
Dong, Weiguo; Embury, Christine M; Lu, Yaman et al. (2016) The mixed-lineage kinase 3 inhibitor URMC-099 facilitates microglial amyloid-β degradation. J Neuroinflammation 13:184
Guo, Dongwei; Zhou, Tian; Araínga, Mariluz et al. (2016) Creation of a Long-Acting Nanoformulated 2',3'-Dideoxy-3'-Thiacytidine. J Acquir Immune Defic Syndr :

Showing the most recent 10 out of 103 publications